This Month in Gastroenterology Jan Tack, John M. Carethers Gastroenterology Volume 135, Issue 2, Pages 331-334 (August 2008) DOI: 10.1053/j.gastro.2008.06.050 Copyright © 2008 AGA Institute Terms and Conditions
Figure 1 Clinical outcomes in ulcerative colitis patients treated by leukocyte or sham apheresis. Gastroenterology 2008 135, 331-334DOI: (10.1053/j.gastro.2008.06.050) Copyright © 2008 AGA Institute Terms and Conditions
Figure 2 Receiver operator characteristic curve for a cross-validated model with P16 loss as a predictor of lack of response to photodynamic therapy (adjusted for clinical variables). Gastroenterology 2008 135, 331-334DOI: (10.1053/j.gastro.2008.06.050) Copyright © 2008 AGA Institute Terms and Conditions
Figure 3 Mutations in fecal DNA and TNM stage. The horizontal bars shows the median fraction of mutant DNA. The whiskers represent the minimum and maximum values that were found for each indicated stage. Gastroenterology 2008 135, 331-334DOI: (10.1053/j.gastro.2008.06.050) Copyright © 2008 AGA Institute Terms and Conditions
Figure 4 Quantification of initial injury and subsequent regeneration using 2-dimensional fluorescent intensity profiles of cerulein-mediated injury in mouse pancreata. The upper panel demonstrated similar reductions in amylase staining in each group on day 2, indicating similar severity of initial cerulein-mediated (Cae) injury in each group. In the lower panel, failure to generate amylase-expressing cells on day 7 is seen in the setting of either pharmacologic or genetic blockade of hedgehog signaling. Either systemic blockade of hedgehog signaling by cyclopamine (Cae+Cyc), or deletion of Smoothened either throughout the pancreatic epithelium (Pdx-Cre;smofl/fl Cae) or specifically in acinar cells (Ela-CreERT2;smofl/fl Cae) results in failure to regenerate exocrine cell mass. Wt, wild-type mice; PBS, phosphate-buffered saline, a negative control. Gastroenterology 2008 135, 331-334DOI: (10.1053/j.gastro.2008.06.050) Copyright © 2008 AGA Institute Terms and Conditions